BMY vs. MRK, update

Barron’s has an article on this topic as well, coming to similar conclusions. It endorses Novartis (NVS), partly because it has a sizable toe in the generic drug business, which should benefit from a wave of expiring patents. See A Prescription for Profiting From Drug Stocks

This entry was posted on Sunday, July 10th, 2011 at 23:00 and is filed under Healthcare. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.